MND NZ welcomes research into the prevalence of motor neurone disease as we work to better understand this disease in the hope to one day find a cure. The Global Burden of Disease (GBD) study released this week suggests rates in New Zealand may be higher than elsewhere in the world.
We plan to meet with the researchers soon to gain a better understanding of the report’s finding and its implications, in the meantime we’ve spoken to our neurologist clinical advisor, Dr Andrew Chancellor, and MND researcher at the Centre for Brain Research Dr Emma Scotter to provide some further information to consider in relation to the study’s findings.
They provided some definitions:
Motor Neuron Disease: Usually understood to mean the group of diseases affecting the upper and/or lower motor neurons that comprises; amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, and progressive bulbar palsy.
The GBD study also included spinal muscular atrophy, hereditary spastic paraplegia, and pseudobulbar palsy, making it a study of motor neuron diseases, plural.
Incidence rate: The number of people (per 100,000 people) who receive a new diagnosis of a particular disease or in this case diseases, in a given year.
Mortality rate: The number of people (per 100,000) who die in one year of a given cause, in this case any of the named motor neuron diseases. Mortality rates depend upon both how long people live with a disease and the incidence rate of that disease.
And provided commentary on the major media messages:
Message 1: That NZ has the highest mortality rate from MNDs in the world, a rate five times the global average.
Message 2: That our high mortality rate from MNDs is due to a shortage of neurologists. Early diagnosis would slow progression and thus reduce mortality.
At the time of writing, MND New Zealand provide support to 350 people living with MND and their families nationwide. We also provide support to a small number of people and their families who are working through the diagnostic process.
Promising research results announced this week from an Australian clinical trial using a compound called copper-ATSM show that the drug is safe and effective in the effort to defeat Motor Neurone Disease. It has taken the Melbourne-based research team 15 years of working with the compound to get to this […] READ MORE
For further details on the presentations and presenters from this year’s symposium, please go to https://www.mndassociation.org/symposium/. You may also be interested in the cleverly designed ‘Periodic Table of MND Research’ summary of the symposium here https://www.mndassociation.org/symposium/symposium-live/ A huge thank you to the MND Association of England, Wales and Northern Ireland for sharing […] READ MORE